Joyce Tsai
Vice President of Clinical Sciences at Compass Pathways
Data updated
Research Footprint
Joyce Tsai appears in 6 tracked papers (2022–2026), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Suicidality.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Guy Goodwin, Lindsey Marwood and Ekaterina Malievskaia.
Background & Research
Joyce Tsai, PhD, is a clinical sciences executive at Compass Pathways, where she has been publicly identified as Vice President of Clinical Sciences. She appears as an author on multiple Compass psilocybin depression papers, including work on treatment-resistant depression, SSRI coadministration, antidepressant discontinuation, and the subjective psychedelic experience.
Key Impact
She is a clinical-science leader on the Compass Pathways psilocybin program, helping drive some of the most visible contemporary trials of psilocybin for treatment-resistant depression.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Joyce Tsai is associated with.